Hyderabad: Bharat Serums and Vaccines (BSV), one of the fastest growing biopharmaceutical companies in India, has laid the foundation stone for a new bio-pharmaceutical manufacturing plant in Genome Valley here on Thursday .
To cater to Domestic and Export markets including regulated markets like USA and EU, the new facility will cover an area of 10 acres and involve an investment of INR 200 crore, the company said in a release here.
Currently, BSV has a manufacturing facility in Ambernath in Maharashtra that caters to domestic and more than 80 export markets and a manufacturing facility in Aachen, Germany, that serves the international markets.
With this Manufacturing Facility, BSV aims to significantly increase its capacity in producing injectables with the commissioning of the fill-finish formulation line in phase 1 and an additional multi-product line in phase 2 of the project.
The manufacturing facility endeavours to produce world-class products that adhere to International Quality Systems while complying to the Indian regulatory norms of Schedule M as well as the Global regulatory requirements in the world.
The facility will produce women health products, rabies vaccines, immunoglobulins, hormones, among others.
The facility will be based out of Genome Valley, which is India’s first organized cluster for Life Sciences R&D and Clean Manufacturing activities, with world-class infrastructure facilities in the form of Industrial / Knowledge Parks, Special Economic Zones (SEZs), Multi-tenanted dry and wet laboratories and incubation facilities.
Amongst the top 10 Biotech companies in India, the Company has in its portfolio over 145 brands.
The company has over 2500 employees selling its products across the country with their brands being marketed all over India and exported to over 70 countries across the world.
It aims to provide long-term employment opportunities to the people of the Telangana State as well as upskilling of capabilities.
Telangana IT and Industries Minister K.T Rama Rao laid the foundation in the presence of Mr. E V Narasimha Reddy, Vice Chairman and Managing Director, TSIIC, Mr. Shakthi M Nagappan, CEO, Telangana Lifesciences and BSV Managing Director and CEO Mr. Sanjiv Navangul.
Speaking on the occasion, KTR said, “ We welcome BSV to the “Vaccine Capital of the World” and are delighted that they have chosen Genome Valley to host their world class manufacturing facility. This reflects the huge opportunity, potential and the comprehensive ecosystem that Genome Valley offers to the life sciences sector, that truly makes Telangana a biotech hub focusing on innovating in India for India and the world.
Sanjiv Navangul, said, “We are delighted to be a part of the Genome Valley ecosystem that promotes research and innovation and provides a conducive scientific temper for bio-pharma companies to operate.
The support received from the State of Telangana has been encouraging and we are confident that we will be able to collectively work together to deliver research- driven products to our patients.”
With this new bio-pharma manufacturing facility, we are no hopeful to serve the health needs of patients in India and across the globe, he added.